Navigation Links
UC to test targeted treatment for prostate cancer
Date:4/16/2010

CINCINNATIThe American Cancer Society estimates one man in six will get prostate cancer during his lifetime, making it the second-leading cause of cancer death in men. With a new partnership with Areva Med, UC researchers will investigate the use of a new drug in stopping the growth of prostate cancer tumors.

In the study, UC researchers in the lab of Zhongyun Dong, PhD, will test the efficacy of a new agent targeted against a specific protein on the surface of the tumor.

"It's been shown that human prostate cancer cells overexpress some proteins on their surface," says Dong, an associate professor of hematology oncology in the department of internal medicine. "This overexpression presents a novel target for management of advanced prostate cancer."

Dong says previous radiation therapy targeting these proteins has been shown to inhibit tumor growth in several animal models. UC's study will be the first to explore this approach for prostate tumors. In the work, researchers will bind the isotope 212-lead to an antibody targeting one of these proteins.

"When administered intravenously, the AREVA Med 2120lead-antibody is designed to bind to the tumor's surface, emit alpha particles in and selectively destroy the tumor cells," says Dong.

In the study, expected to run through the end of the year, researchers will measure the toxicity of the treatment and its efficacy in inhibiting cancer cell growth. Data will then be gathered to support phase-1 clinical trials in patients with advanced prostate cancer.

According to hematology oncology professor Olivier Rixe, MD, PhD, the agent represents a more targeted radiation therapy for cancer treatment. Rixe is the director of the UC's recently launched phase-1 clinical trials unit at the newly established Early Drug Development Program.

"Targeting a monoclonal antibody against this protein is not new," says Rixe. "What's new is that we will load the antibody with a
'/>"/>

Contact: Katy Cosse
kathryn.cosse@uc.edu
513-558-0207
University of Cincinnati Academic Health Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
2. Microarray sequence capture speeds large-scale resequencing of targeted genomic regions
3. Researchers combat slowing yields with targeted fertilizer applications
4. Fishing throws targeted species off balance, Scripps study shows
5. New technique allows targeted inactivation of genes in research model
6. Newly identified role for power plants in human cells could lead to targeted therapies
7. Consortium develops new method enabling routine targeted gene modification
8. On the trail of a targeted therapy for blood cancers
9. Cellular discovery may lead to targeted treatment for rare form of anemia
10. Molecular fingerprints point the way to earlier cancer diagnosis and more targeted treatment
11. Targeted drug therapy prevents exercise-induced arrhythmias
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/8/2015)... , April 8, 2015  Infinisource, a leading ... services, and Morpho, a leading supplier of biometric ... produce the market,s most advanced biometrically-enabled time clock, ... NXG time clock is setting a bold, new ... data for the small and mid-size employer. When ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... can produce biodiesel fuel from municipal sewage sludge that is ... conventional diesel refined from petroleum, according to an article in ... is the solid material left behind from the treatment of ... out in the article that demand for biodiesel has led ...
... part of a healthy diet, can increase the levels ... cholesterol, according to an international team of nutritional scientists., ... lowering lipids and lipoproteins, which are a risk factor ... nutrition, Penn State. "This new study shows an additional ...
... the lowly lamprey eel have identified an overlooked nervous ... circuitry in vertebrates such as birds, fishes and mammals. ... , online May 16, and highlighted in the magazine,s ... Illinois at Chicago professor of biological sciences and the ...
Cached Biology News:Pistachios offer multiple benefits 2Pistachios offer multiple benefits 3Parallel brainstem circuit discovery suggests new path in Parkinson's research 2
(Date:5/4/2015)... Boston, MA (PRWEB) May 04, 2015 ... solutions for drug discovery and life science research, ... 5.0 , the latest version of its enterprise ... for biopharma R&D enables more efficient discovery and ... holistic approach to integrate and address protein optimization ...
(Date:5/4/2015)... , May 4, 2015  Soligenix, Inc. (OTCQB: ... developing products that address unmet medical needs in the ... it will be presenting preclinical data from three of ... Defense Science and Technology Conference on May 12-14, 2015 ... at 701 Convention Plaza, St. Louis MO ...
(Date:5/4/2015)... - New Massive Open Online ... for the United States Medical Licensing Examination ... and medical information products and services, announced today that ... Course) designed to help medical students prepare for the ... first and most daunting of the three exams medical ...
(Date:5/4/2015)... May 4, 2015   Intrexon Corporation (NYSE: ... quarter 2015 financial results after the market closes on ... call that day at 5:30 PM ET to discuss ... The conference call may be accessed by dialing ... join the "Intrexon Conference Call."  Participants may also access ...
Breaking Biology Technology:Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 2Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 3Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 5Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 6Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 7Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 8Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 9Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 10Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 11Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 12Elsevier's Free MOOC Prepares Med Students for Licensing Exam 2Elsevier's Free MOOC Prepares Med Students for Licensing Exam 3Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2
... CardioDex announces initial commercial use ... from commercial use of the device on 41 patients at ... and no complications. "We are very excited about these new ... for a major unmet medical need due to the increasing ...
... Pa., May 1, 2012  Discovery Laboratories, Inc. (NASDAQ: ... new pharmacoeconomic analysis demonstrating that the lower rate of ... , when compared with infants treated with Curosurf ® ... leading surfactants, also resulted in a potential hospital cost ...
... 2012 /PRNewswire-Asia/ -- 3SBio Inc. (NASDAQ: SSRX ) ... focused on researching, developing, manufacturing and marketing biopharmaceutical products, ... Report on Form 20-F for the fiscal year ended ... Commission on April 30, 2012. The annual report on ...
Cached Biology Technology:New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy 2New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy 3Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants 2Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants 3Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants 4Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants 5
The VersArray hybridization chamber is used for manual (coverslip) hybridization of microarrays. The chamber accommodates 2 slides and is watertight to allow incubation of slides in a water bath. Dim...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
... solid. PROTECT FROM LIGHT. Useful in cell activation experiments ... ≥98% by TLC. Soluble in DMSO or EtOH. ... 10 mM stock in DMSO is recommended. Microliter amounts ... O with rapid mixing (e.g. 10 μl into 5 ...
Monoclonal antibodies conjugated with rhodamine...
Biology Products: